{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T02:38:55Z","timestamp":1771036735923,"version":"3.50.1"},"reference-count":137,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Leo Pharma"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Cancer-associated thrombosis (CAT) is a leading cause of death among patients with cancer. CAT can manifest itself as venous thromboembolism (VTE), in the form of deep vein thrombosis or pulmonary embolism, or arterial thromboembolism. The pathophysiology of CAT is complex and depends on cancer-, patient-, treatment- and biomarkers-related factors. Treatment of VTE in patients with cancer is complex and includes three major classes of anticoagulant agents: heparin and its derivatives, e.g., low molecular weight heparins, direct oral anticoagulants (DOACs), and vitamin K inhibitors. Given the tremendous heterogeneity of clinical situations in patients with cancer and the challenges of CAT, there is no single universal treatment option for patients suffering from or at risk of CAT. Initial studies suggested that patients seemed to prefer an anticoagulant that would not interfere with their cancer treatment, suggesting the primacy of cancer over VTE, and favoring efficacy and safety over convenience of route of administration. Recent studies show that when the efficacy and safety aspects are similar, patients prefer the oral route of administration. Despite this, injectables are a valid option for many patients with cancer.<\/jats:p>","DOI":"10.3390\/cancers15184640","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T01:32:50Z","timestamp":1695173570000},"page":"4640","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Role of Injectables in the Treatment and Prevention of Cancer-Associated Thrombosis"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8934-2936","authenticated-orcid":false,"given":"Mariasanta","family":"Napolitano","sequence":"first","affiliation":[{"name":"Haematology Unit, Thrombosis and Haemostasis Reference Regional Center, University of Palermo, 90121 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Siragusa","sequence":"additional","affiliation":[{"name":"Haematology Unit, Thrombosis and Haemostasis Reference Regional Center, University of Palermo, 90121 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1055\/s-0041-1736037","article-title":"Management of Cancer-Associated Thrombosis: Unmet Needs and Future Perspectives","volume":"5","author":"Falanga","year":"2021","journal-title":"TH Open"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"I17","DOI":"10.1161\/01.CIR.0000078466.72504.AC","article-title":"Venous thromboembolism and cancer: Risks and outcomes","volume":"107","author":"Lee","year":"2003","journal-title":"Circulation"},{"key":"ref_3","unstructured":"Abu Zaanona, M.I., and Mantha, S. (2022). StatPearls, StatPearls."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaccao.2021.03.001","article-title":"Venous and Arterial Thromboembolism in Patients With Cancer: JACC: CardioOncology State-of-the-Art Review","volume":"3","author":"Gervaso","year":"2021","journal-title":"JACC CardioOncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","article-title":"Cancer-associated venous thromboembolism","volume":"8","author":"Khorana","year":"2022","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline","volume":"34","author":"Falanga","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"Farge","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update","volume":"38","author":"Key","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update","volume":"41","author":"Key","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: Prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.chest.2021.07.056","article-title":"Executive Summary: Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1002\/onco.13596","article-title":"Update on Guidelines for the Management of Cancer-Associated Thrombosis","volume":"26","author":"Streiff","year":"2021","journal-title":"Oncologist"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/jth.14219","article-title":"Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: Guidance from the SSC of the ISTH","volume":"16","author":"Khorana","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/archinte.160.6.809","article-title":"Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study","volume":"160","author":"Heit","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: A population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1093\/eurheartj\/ehab171","article-title":"Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer-a nationwide analysis","volume":"42","author":"Grilz","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Abdol Razak, N.B., Jones, G., Bhandari, M., Berndt, M.C., and Metharom, P. (2018). Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment. Cancers, 10.","DOI":"10.3390\/cancers10100380"},{"key":"ref_19","unstructured":"Kushner, A., West, W.P., Khan Suheb, M.Z., and Pillarisetty, L.S. (2022). StatPearls, StatPearls Publishing."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Canonico, M.E., Santoro, C., Avvedimento, M., Giugliano, G., Mandoli, G.E., Prastaro, M., Franzone, A., Piccolo, R., Ilardi, F., and Cameli, M. (2022). Venous Thromboembolism and Cancer: A Comprehensive Review from Pathophysiology to Novel Treatment. Biomolecules, 12.","DOI":"10.3390\/biom12020259"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/j.seminoncol.2014.04.009","article-title":"Platelets and cancer-associated thrombosis","volume":"41","author":"Connolly","year":"2014","journal-title":"Semin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Lucchesi, A., Napolitano, R., Bochicchio, M.T., Giordano, G., and Napolitano, M. (2021). Platelets Contribution to Thrombin Generation in Philadelphia-Negative Myeloproliferative Neoplasms: The \"Circulating Wound\" Model. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222111343"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6215","DOI":"10.2147\/IJGM.S372038","article-title":"Correlation of Inflammation and Coagulation Markers with the Incidence of Deep Vein Thrombosis in Cancer Patients with High Risk of Thrombosis","volume":"15","author":"Setiawan","year":"2022","journal-title":"Int. J. Gen. Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Di Battista, V., Bochicchio, M.T., Giordano, G., Napolitano, M., and Lucchesi, A. (2021). Genetics and Pathogenetic Role of Inflammasomes in Philadelphia Negative Chronic Myeloproliferative Neoplasms: A Narrative Review. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020561"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ajh.25494","article-title":"Bleeding incidence and risk factors among cancer patients treated with anticoagulation","volume":"94","author":"Angelini","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Shahzad, M.H., Feng, L., Su, X., Brassard, A., Dhoparee-Doomah, I., Ferri, L.E., Spicer, J.D., and Cools-Lartigue, J.J. (2022). Neutrophil Extracellular Traps in Cancer Therapy Resistance. Cancers, 14.","DOI":"10.3390\/cancers14051359"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1093\/annonc\/mds058","article-title":"Cancer effect on periprocedural thromboembolism and bleeding in anticoagulated patients","volume":"23","author":"Tafur","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"103782","DOI":"10.1016\/j.critrevonc.2022.103782","article-title":"Venous thromboembolism in cancer and cancer immunotherapy","volume":"178","author":"Kacimi","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jjcc.2018.02.011","article-title":"Mechanism and management of cancer-associated thrombosis","volume":"72","author":"Mukai","year":"2018","journal-title":"J. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1160\/TH16-08-0615","article-title":"Cancer-associated venous thromboembolism: Burden, mechanisms, and management","volume":"117","author":"Ay","year":"2017","journal-title":"Thromb. Haemost."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1002\/onco.13569","article-title":"Prediction and Prevention of Cancer-Associated Thromboembolism","volume":"26","author":"Khorana","year":"2021","journal-title":"Oncologist"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(18)30063-2","article-title":"A clinical prediction model for cancer-associated venous thromboembolism: A development and validation study in two independent prospective cohorts","volume":"5","author":"Pabinger","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"JAMA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/archinte.166.4.458","article-title":"Incidence of venous thromboembolism and its effect on survival among patients with common cancers","volume":"166","author":"Chew","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S0049-3848(14)50007-2","article-title":"Risk factors for venous thromboembolism in cancer: Novel findings from the Vienna Cancer and Thrombosis Study (CATS)","volume":"133","author":"Konigsbrugge","year":"2014","journal-title":"Thromb. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1111\/j.1538-7836.2004.00928.x","article-title":"The risk of a venous thrombotic event in lung cancer patients: Higher risk for adenocarcinoma than squamous cell carcinoma","volume":"2","author":"Blom","year":"2004","journal-title":"J. Thromb. Haemost."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.thromres.2005.10.015","article-title":"Chemotherapy-induced thrombosis","volume":"118","author":"Haddad","year":"2006","journal-title":"Thromb. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1200\/JCO.2011.40.1810","article-title":"Tumor grade is associated with venous thromboembolism in patients with cancer: Results from the Vienna Cancer and Thrombosis Study","volume":"30","author":"Ahlbrecht","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3324\/haematol.2012.073338","article-title":"Regional lymph node metastases are a strong risk factor for venous thromboembolism: Results from the Vienna Cancer and Thrombosis Study","volume":"98","author":"Dickmann","year":"2013","journal-title":"Haematologica"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"136","DOI":"10.6004\/jnccn.2017.7037","article-title":"Description of Venous Thromboembolism in Hospitalized Patients With Metastatic Cancer: A National Sample","volume":"16","author":"Mohammed","year":"2018","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1002\/cam4.4027","article-title":"Cardiovascular events in cancer patients with bone metastases-A Danish population-based cohort study of 23,113 patients","volume":"10","author":"Asdahl","year":"2021","journal-title":"Cancer Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1161\/ATVBAHA.120.314378","article-title":"Cancer Therapy-Associated Thrombosis","volume":"41","author":"Grover","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/01.sla.0000193959.44677.48","article-title":"A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: The @RISTOS project","volume":"243","author":"Agnelli","year":"2006","journal-title":"Ann. Surg."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1097\/CORR.0000000000000463","article-title":"High Risk of Venous Thromboembolism After Surgery for Long Bone Metastases: A Retrospective Study of 682 Patients","volume":"476","author":"Groot","year":"2018","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.thromres.2018.11.012","article-title":"Incidence, risk factors, and outcomes of venous thromboembolism after oncologic surgery: A systematic review and meta-analysis","volume":"173","author":"Li","year":"2019","journal-title":"Thromb. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"C2","DOI":"10.1093\/eurheartj\/suaa004","article-title":"Pharmacological cancer treatment and venous thromboembolism risk","volume":"22","author":"Ramirez","year":"2020","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1200\/JCO.2011.35.5669","article-title":"High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: A large retrospective analysis","volume":"29","author":"Moore","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1002\/cncr.24508","article-title":"Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: A Danish population-based cohort study","volume":"115","author":"Hernandez","year":"2009","journal-title":"Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1200\/JCO.1996.14.10.2731","article-title":"Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group","volume":"14","author":"Pritchard","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1002\/ijc.30280","article-title":"Systematic review and meta-analysis of the risk of severe and life-threatening thromboembolism in cancer patients receiving anti-EGFR monoclonal antibodies (cetuximab or panitumumab)","volume":"139","author":"Miroddi","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/annonc\/mdr592","article-title":"Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: A meta-analysis of randomized clinical trials","volume":"23","author":"Petrelli","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.thromres.2021.06.018","article-title":"Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study","volume":"205","author":"Richard","year":"2021","journal-title":"Thromb. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"Farge","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_55","first-page":"1181","article-title":"Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Streiff","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1177\/0269216318815377","article-title":"Oral anticoagulation is preferable to injected, but only if it is safe and effective: An interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial","volume":"33","author":"Hutchinson","year":"2019","journal-title":"Palliat. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.3324\/haematol.2015.127126","article-title":"Assessing patients\u2019 anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology","volume":"100","author":"Noble","year":"2015","journal-title":"Haematologica"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1055\/s-0040-1714739","article-title":"Anticoagulation Treatment in Cancer-Associated Venous Thromboembolism: Assessment of Patient Preferences Using a Discrete Choice Experiment (COSIMO Study)","volume":"121","author":"Picker","year":"2021","journal-title":"Thromb. Haemost."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdz111","article-title":"Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants","volume":"30","author":"Ay","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Grzesk, G., Rogowicz, D., Wolowiec, L., Ratajczak, A., Gilewski, W., Chudzinska, M., Sinkiewicz, A., and Banach, J. (2021). The Clinical Significance of Drug-Food Interactions of Direct Oral Anticoagulants. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168531"},{"key":"ref_61","first-page":"171","article-title":"Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: An expert consensus","volume":"17","author":"Napolitano","year":"2019","journal-title":"Blood Transfus."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1634\/theoncologist.2013-0239","article-title":"New oral anticoagulants and the cancer patient","volume":"19","author":"Short","year":"2014","journal-title":"Oncologist"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1182\/bloodadvances.2019000369","article-title":"Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy","volume":"3","author":"Connors","year":"2019","journal-title":"Blood Adv."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"8559","DOI":"10.1007\/s00520-022-07235-8","article-title":"Complexity and clinical significance of drug\u2013drug interactions (DDIs) in oncology: Challenging issues in the care of patients regarding cancer-associated thrombosis (CAT)","volume":"30","author":"Tsoukalas","year":"2022","journal-title":"Support. Care Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1055\/s-0034-1370791","article-title":"Thrombosis in brain tumors","volume":"40","author":"Jo","year":"2014","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_66","first-page":"e8771","article-title":"Venous Thromboembolism in Patients With Brain Cancer: Focus on Prophylaxis and Management","volume":"12","author":"Kabashneh","year":"2020","journal-title":"Cureus"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s11060-014-1587-y","article-title":"Risk factors for venous thromboembolism in patients undergoing craniotomy for neoplastic disease","volume":"120","author":"Kimmell","year":"2014","journal-title":"J. Neuro-Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1023\/A:1008915202859","article-title":"Venous Thromboembolism Occurs Frequently in Patients Undergoing Brain Tumor Surgery Despite Prophylaxis","volume":"8","author":"Chan","year":"1999","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"101350","DOI":"10.1016\/j.beha.2022.101350","article-title":"Challenges in anticoagulation for patients with brain tumors","volume":"35","author":"Iyengar","year":"2022","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1182\/hematology.2022000411","article-title":"Evidence-Based Minireview: Full dose, modified dose, or no anticoagulation for patients with cancer and acute VTE and thrombocytopenia","volume":"2022","author":"Patell","year":"2022","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1182\/bloodadvances.2022008644","article-title":"The Prevalence of Thrombocytopenia in Patients with Acute Cancer-Associated Thrombosis","volume":"7","author":"Hsu","year":"2022","journal-title":"Blood Adv."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Leader, A., Hofstetter, L., and Spectre, G. (2021). Challenges and Advances in Managing Thrombocytopenic Cancer Patients. J. Clin. Med., 10.","DOI":"10.3390\/jcm10061169"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-030-33330-0_1","article-title":"Frailty: What Is It?","volume":"1216","author":"Proietti","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Scotte, F., Leroy, P., Chastenet, M., Aumont, L., Benatar, V., and Elalamy, I. (2019). Treatment and Prevention of Cancer-Associated Thrombosis in Frail Patients: Tailored Management. Cancers, 11.","DOI":"10.3390\/cancers11010048"},{"key":"ref_75","first-page":"e000610","article-title":"How I treat cancer-associated thrombosis","volume":"5","author":"Moik","year":"2020","journal-title":"ESMO Open"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/rth2.12036","article-title":"Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism","volume":"1","author":"Moustafa","year":"2017","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e000091","DOI":"10.1136\/esmoopen-2016-000091","article-title":"Renal insufficiency and cancer treatments","volume":"1","author":"Janus","year":"2016","journal-title":"ESMO Open"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1002\/onco.13570","article-title":"Approach to Cancer-Associated Thrombosis: Challenging Situations and Knowledge Gaps","volume":"26","author":"Wang","year":"2021","journal-title":"Oncologist"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1111\/jth.12411","article-title":"Impact of chronic kidney disease on the risk of clinical outcomes in patients with cancer-associated venous thromboembolism during anticoagulant treatment","volume":"11","author":"Kooiman","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood.V122.21.2310.2310","article-title":"Treatment of cancer-associated thrombosis","volume":"122","author":"Lee","year":"2013","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/ckj\/sfu080","article-title":"Anticoagulation in chronic kidney disease patients-the practical aspects","volume":"7","author":"Hughes","year":"2014","journal-title":"Clin. Kidney J."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3389\/fmed.2017.00142","article-title":"Cancer-Associated Venous Thromboembolism: A Practical Review Beyond Low-Molecular-Weight Heparins","volume":"4","author":"Smrke","year":"2017","journal-title":"Front. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.3390\/curroncol28060453","article-title":"Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus","volume":"28","author":"Carrier","year":"2021","journal-title":"Curr. Oncol."},{"key":"ref_84","unstructured":"Berlioz, B.E., and Sanghavi, D. (2022). StatPearls, StatPearls."},{"key":"ref_85","unstructured":"Mahat, K.C., Sedhai, Y.R., and Krishnan, P. (2022). StatPearls, StatPearls."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1076029620975489","DOI":"10.1177\/1076029620975489","article-title":"Retrospective Review of Prescribing Patterns in Cancer-Associated Thrombosis: A Single Center Experience in Edmonton, Alberta, Canada","volume":"27","author":"Kaliel","year":"2021","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1046\/j.1365-2141.2002.03233.x","article-title":"Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin","volume":"116","author":"Crowther","year":"2002","journal-title":"Br. J. Haematol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"141S","DOI":"10.1378\/chest.08-0689","article-title":"Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Hirsh","year":"2008","journal-title":"Chest"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1076029608319881","article-title":"Are all low molecular weight heparins equivalent in the management of venous thromboembolism?","volume":"14","author":"Fareed","year":"2008","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_90","first-page":"CD009447","article-title":"Anticoagulation for perioperative thromboprophylaxis in people with cancer","volume":"7","author":"Matar","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1111\/jth.14317","article-title":"Evaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer","volume":"16","author":"Reynolds","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3400\/avd.oa.22-00005","article-title":"Relevance of Non-Bridging Therapy with Heparin during Temporary Interruption of Direct Oral Anticoagulants in Patients with Cancer-Associated Venous Thromboembolism","volume":"15","author":"Oyakawa","year":"2022","journal-title":"Ann. Vasc. Dis."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s11239-023-02780-3","article-title":"Efficacy and safety of prophylaxis for venous thromboembolism in brain neoplasm patients undergoing neurosurgery: A systematic review and Bayesian network meta-analysis","volume":"55","author":"Liu","year":"2023","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_95","first-page":"CD006650","article-title":"Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer","volume":"6","author":"Kahale","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1076029620918290","DOI":"10.1177\/1076029620918290","article-title":"Quality of Life in Patients With Cancer Under Prolonged Anticoagulation for High-Risk Deep Vein Thrombosis: A Long-Term Follow-Up","volume":"26","author":"Napolitano","year":"2020","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0049-3848(86)90340-3","article-title":"Low molecular weight heparin (KABI 2165, Fragmin): Pharmacokinetics after intravenous and subcutaneous administration in human volunteers","volume":"42","author":"Bratt","year":"1986","journal-title":"Thromb. Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/VHRM.S2132","article-title":"Management of venous thromboembolism in patients with cancer: Role of dalteparin","volume":"4","author":"Linkins","year":"2008","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"800","DOI":"10.7326\/0003-4819-130-10-199905180-00003","article-title":"Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials","volume":"130","author":"Gould","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2165\/00003495-199600527-00006","article-title":"Comparison of the efficacy and safety of low molecular weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis. An updated meta-analysis","volume":"52","author":"Leizorovicz","year":"1996","journal-title":"Drugs"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"175","DOI":"10.7326\/0003-4819-140-3-200402030-00008","article-title":"Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: A meta-analysis of randomized, controlled trials","volume":"140","author":"Quinlan","year":"2004","journal-title":"Ann. Intern. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1111\/j.1538-7836.2004.00853.x","article-title":"Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: A prospective cohort study","volume":"2","author":"Monreal","year":"2004","journal-title":"J. Thromb. Haemost."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1177\/0269216307080816","article-title":"The use of long-term low-molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: A case series of sixty two patients","volume":"21","author":"Noble","year":"2007","journal-title":"Palliat. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/jth.12923","article-title":"Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: The DALTECAN Study","volume":"13","author":"Francis","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1177\/1076029617729215","article-title":"The Role of Tinzaparin in Oncology","volume":"24","author":"Dimakakos","year":"2018","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/2162-3619-2-21","article-title":"Tinzaparin and other low-molecular-weight heparins: What is the evidence for differential dependence on renal clearance?","volume":"2","author":"Johansen","year":"2013","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.amjmed.2006.03.030","article-title":"Self-managed long-term low-molecular-weight heparin therapy: The balance of benefits and harms","volume":"120","author":"Hull","year":"2007","journal-title":"Am. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","article-title":"Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer","volume":"119","author":"Hull","year":"2006","journal-title":"Am. J. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.thromres.2012.08.290","article-title":"Long-term treatment of venous thromboembolism with tinzaparin compared to vitamin K antagonists: A meta-analysis of 5 randomized trials in non-cancer and cancer patients","volume":"130","author":"Laporte","year":"2012","journal-title":"Thromb. Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ejvs.2008.11.030","article-title":"A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis","volume":"37","author":"Romera","year":"2009","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1177\/1076029617696581","article-title":"Tinzaparin for Long-Term Treatment of Venous Thromboembolism in Patients With Cancer: A Systematic Review and Meta-Analysis","volume":"24","author":"Mathioudakis","year":"2018","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.thromres.2017.07.004","article-title":"Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study","volume":"157","year":"2017","journal-title":"Thromb. Res."},{"key":"ref_114","first-page":"56","article-title":"Long-term use of tinzaparin for the treatment of cancer-associated thrombosis in clinical practice: Insights from the prospective TROPIQUE study","volume":"47","author":"Frere","year":"2022","journal-title":"J. Med. Vasc."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.amjmed.2008.12.023","article-title":"Home therapy of venous thrombosis with long-term LMWH versus usual care: Patient satisfaction and post-thrombotic syndrome","volume":"122","author":"Hull","year":"2009","journal-title":"Am. J. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1007\/s00228-022-03365-4","article-title":"Tinzaparin-a review of its molecular profile, pharmacology, special properties, and clinical uses","volume":"78","author":"Amerali","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3892\/ol.2022.13235","article-title":"Prophylaxis of cancer-associated venous thromboembolism with low-molecular-weight heparin-tinzaparin: Real world evidence","volume":"23","author":"Christopoulou","year":"2022","journal-title":"Oncol. Lett."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1055\/a-1486-7497","article-title":"Failure of the Ottawa Score to Predict the Risk of Recurrent Venous Thromboembolism in Cancer Patients: The Prospective PREDICARE Cohort Study","volume":"122","author":"Girard","year":"2022","journal-title":"Thromb. Haemost."},{"key":"ref_119","unstructured":"Jupalli, A., and Iqbal, A.M. (2023). StatPearls, StatPearls."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/1076029606293692","article-title":"Secondary prevention of venous thromboembolic events in patients with active cancer: Enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period","volume":"12","author":"Deitcher","year":"2006","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","article-title":"Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: A randomized controlled study","volume":"162","author":"Meyer","year":"2002","journal-title":"Arch. Intern. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e12736","DOI":"10.1002\/rth2.12736","article-title":"Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study","volume":"6","author":"Pedrajas","year":"2022","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_123","unstructured":"Vardanyan, R., and Hruby, V. (2016). Synthesis of Best-Seller Drugs, Academic Press."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/bs.pmbts.2019.02.004","article-title":"The clinical use of Fondaparinux: A synthetic heparin pentasaccharide","volume":"163","author":"Zhang","year":"2019","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1182\/blood-2007-10-120543","article-title":"Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: Focus on new anticoagulant agents","volume":"111","author":"Crowther","year":"2008","journal-title":"Blood"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1160\/TH08-09-0563","article-title":"Treatment of venous thromboembolism in patients with cancer: Subgroup analysis of the Matisse clinical trials","volume":"101","author":"Raskob","year":"2009","journal-title":"Thromb. Haemost."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1001\/archinte.162.16.1833","article-title":"Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: A meta-analysis of 4 randomized double-blind studies","volume":"162","author":"Turpie","year":"2002","journal-title":"Arch. Intern. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fcvm.2016.00024","article-title":"Venous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer Anticoagulants","volume":"3","author":"Qureshi","year":"2016","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1007\/s00520-012-1413-z","article-title":"Investigating the benefit of adding a vena cava filter to anticoagulation with fondaparinux sodium in patients with cancer and venous thromboembolism in a prospective randomized clinical trial","volume":"20","author":"Barginear","year":"2012","journal-title":"Support. Care Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/19336918.2020.1767489","article-title":"The anti-cancer properties of heparin and its derivatives: A review and prospect","volume":"14","author":"Ma","year":"2020","journal-title":"Cell Adhes. Migr."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1158\/1078-0432.CCR-05-1131","article-title":"Differential metastasis inhibition by clinically relevant levels of heparins--correlation with selectin inhibition, not antithrombotic activity","volume":"11","author":"Stevenson","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"70","DOI":"10.5414\/CPP51070","article-title":"Are low molecular weight heparins able to sensitize chemoresistant tumor cells?","volume":"51","author":"Stolting","year":"2013","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"67553","DOI":"10.18632\/oncotarget.18738","article-title":"Heparin antagonizes cisplatin resistance of A2780 ovarian cancer cells by affecting the Wnt signaling pathway","volume":"8","author":"Pfankuchen","year":"2017","journal-title":"Oncotarget"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Karamouzis, M.V., Athanasiadis, I., Samelis, G., Vallilas, C., Bokas, A., Nikolaidi, A., Dimitriadou, A., Sarantis, P., Pistamaltzian, N., and Schizas, D. (2021). The Impact of Thromboprophylaxis on the Survival of Patients with Advanced Pancreatic Cancer. The Pancreatic Cancer and Tinzaparin (PaCT) Study. Cancers, 13.","DOI":"10.3390\/cancers13122884"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s10637-010-9578-0","article-title":"Modulating the interaction of CXCR4 and CXCL12 by low-molecular-weight heparin inhibits hepatic metastasis of colon cancer","volume":"30","author":"Ma","year":"2012","journal-title":"Investig. New Drugs"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.thromres.2020.09.008","article-title":"Temporal trends in first-line outpatient anticoagulation treatment for cancer-associated venous thromboembolism","volume":"196","author":"Delate","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Gornicki, T., Buldys, K., Zielinska, D., and Chabowski, M. (2023). Direct-Acting Oral Anticoagulant Therapy in Cancer Patients-A Review. Cancers, 15.","DOI":"10.3390\/cancers15102697"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/18\/4640\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:54:09Z","timestamp":1760129649000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/18\/4640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,20]]},"references-count":137,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["cancers15184640"],"URL":"https:\/\/doi.org\/10.3390\/cancers15184640","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,20]]}}}